Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less may be more: smaller lung surgery tested against standard removal

NCT ID NCT04937283

Disease control Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of surgery for people with small (≤2 cm) lung adenocarcinoma that does not have aggressive features. One surgery removes only the part of the lung with the tumor (segmentectomy), while the other removes the entire lobe (lobectomy). The goal is to see if the smaller surgery works just as well in preventing the cancer from coming back, while possibly preserving more lung function. About 690 participants will be randomly assigned to one of the two surgeries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 690 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2019

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged 20-79 years old, both male or female; * Tumor size \<= 2cm on preoperative CT scan; * Peripheral solitary nodule or the associated lesion is MIA or less invasive lesion; * Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio \>= 0.25); * Intraoperative frozen section confirmed invasive lung adenocarcinoma with micropapillary and solid subtype negative (\<= 5%); * Intraoperative frozen section indicated the resection margins was free of tumor cells; * Lung function could withstand both lung segmentectomy and lobectomy (FEV1 \> 1.5L or FEV1% \>= 60%); * Eastern Cooperative Oncology Group, 0 to 2; * Volunteer to participate the trial and sign the informed consent, able to comply with the follow-up plan and other program requirements. Exclusion Criteria: * Radiological pure ground glass nodules (consolidation to tumor ratio \< 0.25); * The nodule is close to the lung hilus and is unable to perform segmentectomy; * Intraoperative frozen section confirmed with micropapillary and solid subtype positive (\> 5%); * Intraoperative frozen section confirmed adenocarcinoma in situ and minimally invasive adenocarcinoma; * Preoperative imaging examination or EBUS indicated lymph node positive metastasis; * Preoperative imaging examination revealed distant metastasis; * Patients with severe damage to heart, liver and kidney function (grade 3 \~ 4, ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit); * Patients with other malignant tumors; * Pregnant, planned pregnancy and lactating female patients (urine HCG\>2500IU/L is diagnosed as early pregnancy); * Prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects; * Those who have participated in other tumor-related clinical trials within three months; * Those are not suitable for participating in trials according to investigator's assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Nantong University

    RECRUITING

    Nantong, Jiangsu, 226001, China

  • Affiliated Hospital of Xuzhou Medical University

    RECRUITING

    Xuzhou, Jiangsu, China

  • Anhui Chest Hospital

    RECRUITING

    Hefei, Anhui, China

  • Huadong Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Huzhou Central Hospital

    RECRUITING

    Huzhou, Zhejiang, China

  • Nanyang Central Hospital

    RECRUITING

    Nanyang, Henan, China

  • Ningbo First Hospital

    RECRUITING

    Ningbo, Zhejiang, China

  • Ningbo No.2 Hospital

    RECRUITING

    Ningbo, Zhejiang, China

  • Shandong Public Health Clinical Center

    RECRUITING

    Jinan, Shandong, China

  • Shanghai Pulmonary Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200433, China

  • The First Affiliated Hospital of University of Science and Technology of China

    RECRUITING

    Hefei, Anhui, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

  • The Sixth People's Hospital of Nantong

    RECRUITING

    Nantong, Jiangsu, 216002, China

  • Yancheng First People's Hospital

    RECRUITING

    Yancheng, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.